- Home
- CYBN vs FDMT Comparison
CYBN vs FDMT Comparison
Compare CYBN & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- FDMT
- Stock Information
- Founded
- CYBN 2019
- FDMT 2013
- Country
- CYBN Canada
- FDMT United States
- Employees
- CYBN N/A
- FDMT N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- CYBN Health Care
- FDMT Health Care
- Exchange
- CYBN Nasdaq
- FDMT Nasdaq
- Market Cap
- CYBN 174.9M
- FDMT 207.1M
- IPO Year
- CYBN N/A
- FDMT 2020
- Fundamental
- Price
- CYBN $7.71
- FDMT $4.13
- Analyst Decision
- CYBN Strong Buy
- FDMT Buy
- Analyst Count
- CYBN 4
- FDMT 10
- Target Price
- CYBN $86.00
- FDMT $32.33
- AVG Volume (30 Days)
- CYBN 310.7K
- FDMT 432.1K
- Earning Date
- CYBN 08-07-2025
- FDMT 08-07-2025
- Dividend Yield
- CYBN N/A
- FDMT N/A
- EPS Growth
- CYBN N/A
- FDMT N/A
- EPS
- CYBN N/A
- FDMT N/A
- Revenue
- CYBN N/A
- FDMT $23,000.00
- Revenue This Year
- CYBN N/A
- FDMT $14,927.03
- Revenue Next Year
- CYBN N/A
- FDMT N/A
- P/E Ratio
- CYBN N/A
- FDMT N/A
- Revenue Growth
- CYBN N/A
- FDMT N/A
- 52 Week Low
- CYBN $4.81
- FDMT $2.24
- 52 Week High
- CYBN $13.88
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- CYBN 50.59
- FDMT 54.45
- Support Level
- CYBN $7.50
- FDMT $4.21
- Resistance Level
- CYBN $9.20
- FDMT $4.62
- Average True Range (ATR)
- CYBN 0.56
- FDMT 0.30
- MACD
- CYBN -0.12
- FDMT -0.02
- Stochastic Oscillator
- CYBN 27.06
- FDMT 37.42
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.